28.33
0.49 (1.76%)
| Previous Close | 27.84 |
| Open | 26.95 |
| Volume | 4,851,387 |
| Avg. Volume (3M) | 6,365,735 |
| Market Cap | 20,275,812,352 |
| Price / Sales | 1.44 |
| Price / Book | 4.64 |
| 52 Weeks Range | |
| Earnings Date | 28 May 2026 |
| Operating Margin (TTM) | -4,823.84% |
| Diluted EPS (TTM) | -0.750 |
| Quarterly Revenue Growth (YOY) | -16.10% |
| Quarterly Earnings Growth (YOY) | -96.70% |
| Total Debt/Equity (MRQ) | 1.93% |
| Current Ratio (MRQ) | 33.47 |
| Operating Cash Flow (TTM) | -839.45 M |
| Levered Free Cash Flow (TTM) | -375.20 M |
| Return on Assets (TTM) | -10.73% |
| Return on Equity (TTM) | -12.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Roivant Sciences Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -5.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.40 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 30.31% |
| % Held by Institutions | 83.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Qvt Financial Lp | 31 Dec 2025 | 26,387,021 |
| Sb Investment Advisers (Uk) Ltd | 31 Dec 2025 | 16,413,603 |
| Two Seas Capital Lp | 31 Dec 2025 | 9,791,891 |
| Rubric Capital Management Lp | 31 Dec 2025 | 9,000,000 |
| Patient Square Capital Lp | 31 Dec 2025 | 8,166,047 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 35.00 (Citigroup, 23.54%) | Buy |
| Median | 34.00 (20.01%) | |
| Low | 30.00 (Guggenheim, 5.90%) | Buy |
| Average | 33.00 (16.48%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 28.18 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Mar 2026 | 34.00 (20.01%) | Buy | 29.52 |
| 10 Feb 2026 | 33.00 (16.48%) | Buy | 27.35 | |
| Citigroup | 10 Feb 2026 | 35.00 (23.54%) | Buy | 27.35 |
| Guggenheim | 09 Feb 2026 | 30.00 (5.89%) | Buy | 27.67 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FITZGERALD MEGHAN | - | 27.35 | -70,000 | -1,914,500 |
| GLINE MATTHEW | - | 27.06 | -358,510 | -9,861,291 |
| HUMES JENNIFER | - | 27.70 | -14,526 | -402,370 |
| PULIK RICHARD | - | 27.70 | -1,546 | -42,824 |
| SUKHATME MAYUKH | - | 27.06 | -217,321 | -5,981,338 |
| Aggregate Net Quantity | -661,903 | |||
| Aggregate Net Value ($) | -18,202,324 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 27.28 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SUKHATME MAYUKH | Officer | 31 Mar 2026 | Disposed (-) | 187,512 | 27.70 | 5,194,082 |
| GLINE MATTHEW | Officer | 31 Mar 2026 | Disposed (-) | 304,684 | 27.70 | 8,439,747 |
| SUKHATME MAYUKH | Officer | 30 Mar 2026 | Disposed (-) | 29,809 | 26.41 | 787,256 |
| SUKHATME MAYUKH | Officer | 30 Mar 2026 | Option execute | 58,391 | - | - |
| GLINE MATTHEW | Officer | 30 Mar 2026 | Disposed (-) | 53,826 | 26.41 | 1,421,545 |
| GLINE MATTHEW | Officer | 30 Mar 2026 | Option execute | 97,319 | - | - |
| FITZGERALD MEGHAN | Director | 26 Mar 2026 | Sell (-) | 70,000 | 27.35 | 1,914,500 |
| FITZGERALD MEGHAN | Director | 26 Mar 2026 | Option execute | 70,000 | - | - |
| HUMES JENNIFER | Officer | 20 Mar 2026 | Disposed (-) | 14,526 | 27.70 | 402,370 |
| PULIK RICHARD | Officer | 20 Mar 2026 | Disposed (-) | 1,546 | 27.70 | 42,824 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |